Fibrobiologics, INC. (FBLG) — DEF 14A Filings

All DEF 14A filings from Fibrobiologics, INC.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (4)

FibroBiologics Seeks Reverse Split, Share Issuance Approvals — Dec 29, 2025 Risk: high
FibroBiologics, Inc. (FBLG) is calling a Special Meeting of Stockholders on February 20, 2026, to address critical corporate actions. The primary proposal is to
FibroBiologics Seeks Reverse Split, Massive Share Issuances — Dec 18, 2025 Risk: high
FibroBiologics, Inc. (FBLG) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, aimed at maintaining Nasdaq listi
FibroBiologics Files 2024 Proxy Statement — Apr 23, 2025 Risk: low
FibroBiologics, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details informat
FibroBiologics Files Definitive Proxy Statement — Jul 8, 2024 Risk: low
FibroBiologics, Inc. filed a definitive proxy statement (DEF 14A) on July 8, 2024. The filing pertains to the company's annual meeting and related matters. The

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX